Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-07-15
2008-07-15
Ketter, James (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093210, C800S018000
Reexamination Certificate
active
07399751
ABSTRACT:
The present invention provides a method of providing an individual with a biological factor or intermediate thereof which comprises introducing into the individual Sertoli cells genetically altered to produce the biological factor or intermediate thereof. The genetically altered Sertoli cells are administered in an amount effective to produce the desired effect. Aside from producing the biological factor or intermediate thereof, the engineered Sertoli cells also create an immunologically privileged site. Vectors comprising a promoter which functions in Sertoli cells operably linked to coding sequence for a desired biological factor are also provided as are Sertoli cells comprising such vectors. A pharmaceutical composition comprising Sertoli cells genetically altered to produce a biological factor is also provided.
REFERENCES:
patent: 5082670 (1992-01-01), Gage et al.
patent: 5236838 (1993-08-01), Rasmussen et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5451660 (1995-09-01), Builder et al.
patent: 5521070 (1996-05-01), Meulien
patent: 5591625 (1997-01-01), Gerson et al.
patent: 5633150 (1997-05-01), Wood et al.
patent: 5663304 (1997-09-01), Builder et al.
patent: 5702700 (1997-12-01), Sanberg et al.
patent: 5725854 (1998-03-01), Selawry
patent: 5759534 (1998-06-01), Selawry
patent: 5759536 (1998-06-01), Bellgrau et al.
patent: 5830460 (1998-11-01), Sanberg et al.
patent: 5849285 (1998-12-01), Selawry
patent: 5958404 (1999-09-01), Selawry
patent: 5969211 (1999-10-01), Burns et al.
patent: 2004/0086494 (2004-05-01), John
patent: 0 260 148 (1988-03-01), None
patent: WO 95/32627 (1995-12-01), None
patent: WO 95/28167 (2005-03-01), None
patent: WO 2005/018540 (2005-03-01), None
Ciotti et al. Evidence for Overlapping Active Aites for 17alpha Ethynlestradiol and Bilirubin in the Human Major Bilirubin UDPglucoronosyltransferase Biochemistry 35:101 19-10124, 1996.
Ciotti et al. Evidence for Overlapping Active Aites for 17alpha Ethynlestradiol and Bilirubin in the Human Major Bilirubin□□UDpglucoronosyltransferase Biochemistry 35:101 19-10124, 1996.
Verma et al., Nature, vol. 389, 1997, pp. 239-242.
Anderson, Nature, vol. 392, 1998, pp. 25-30.
Juengst, Brit. Med. J., vol. 326, pp. 1410-1411.
MacGregor G.R. et al., “Construction of Plasmids that ExpressE.coli-Galactosidase in Mammalian Cells”, 17(6):2365 (1989), XP-000032246.
Okayama H. et al., “A cDNA Cloning Vector that Permits Expression of cDNA Inserts in Mammalian Cells”,Molecular&Cellular Biology 3(2):280-289 (1983), XP-008020929.
Groskreutz D. et al., “CAT Reporter Systems: New pCAT® 3 Reporter Vectors and Antibodies Provide Increased Expression and Detection Capabilities”,Promega Notes Magazine 55(2):1-7 (1996), XP-002278388.
Muramatsu T. et al., “Foreign Gene Expression in the Mouse Testis by Localized In Vivo Gene Transfer”,Biochemical and Biophysical Research Communications 233(1):45-49 (1997), XP-002099972.
Seppen J. et al., “Transplantation of Gunn Rats with Autologous Fibroblasts Expressing Bilirubin UDP-Glucuronosyltransferase: Correction of Genetic Deficiency and Tumor Formation”,Human Gene Therapy 8(1):27-36 (1997), XP-009030118.
Wang L. et al., “A Factor IX-Deficient Mouse Model for Hemophilia B Gene Therapy”,Proc. Natl. Acad. Sci. USA 94(21):11563-11566 (1997), XP-002278403.
Korbutt G.S. et al., “Cotransplantation of Allogeneic Islets with Allogeneic Testicular Cell Aggregates Allows Long-Term Graft Survival Without Systemic Immunosuppression”,Diabetes 46:317-322 (1997), XP-002962502.
Ducray A. et al., “Establishment of a Mouse Sertoli Cell Line Producing Rat Androgen-Binding Protein (ABP)”,Steroids 63(5-6):285-287 (1998), XP-004132212.
Blanchard et al., Adenovirus-Mediated Gene Transfer to Rat Testis in Vivo. Biology of Reproduction. 1997, vol. 56, pp. 495-500.
Dufour et al., “Transgenic Sertoli Cells as a Vehicle for Gene Therapy”,Cell Transplantation, 13:1-6 (2004).
Gage, F., “Cell Therapy”,Nature, 392:18-24 (1998).
Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans, Final Guidance,U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research(CBER), dated Apr. 2003.
Guttenbach et al., “Cytogenic characterization of the TM4 mouse Sertoli cell line. I. Conventional banding techniques, FISH and SKY”,Cytogenet Cell Genet, 94:71-78 (2001).
Hohmeier et al., “Islets for all?”,Nature Biotechnology, 23:1231-1232 (2005).
Mather, J., “Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines”,Biology of Reproduction, 23:243-252 (1980).
McClure et al., “Constitutive Fas Ligand Gene Transcription in Sertoli Cells Is Regulated by Sp1”,The Journal of Biological Chemistry, 274(12):7756-7762 (1999).
Sun et al., “The Minimal Set of Genetic Alterations Required by Conversion of Primary Human Fibroblasts to Cancer Cells in the Subrenal Capsule Assay”,Neoplasia, 7(6):585-593 (2005).
On-Line Medical Dictionary, “Primary cell”, <http://cancerweb.ncl.ac.uk/omd/>, Mar. 6, 1998.
U.S. Appl. No. 08/726,531, filed Oct. 7, 1996, John, Constance M.
U.S. Appl. No. 09/131,501, filed Aug. 9, 1998, Hall, Deborah E.
Al-Hendy, et al., Correction of the Growth Defect in Dwarf Mice with Nonautologous Microencapsulated Myoblasts—An Alternate Approach to Somatic Gene Therapy,Human Gene Therapy6: 165-175, 1995.
Arenas, E., et al., Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo,Nature367: 368-371, 1994.
Bramson J., et al., The use of adenoviral vectors for gene therapy and gene transfer in vivo,Current Opinion in Biotechnol. 6: 590-595, 1995.
Cheng, J., et al., Protection from Fas-Mediated Apoptosis by a Soluble Form of the Fas Molecule,Science263(5154): 1759-1762,1994.
Chervonsky, A., et al., The Role of Fas in Autoimmune Diabetes,Cell89: 17-24, 1997.
Connelly, S., et al., Sustained Expression of Therapeutic Levels of Human Factor VIII in Mice,Blood87: 4671-4677, 1966.
Crystal, R., Transfer of Genes to Humans: Early Lessons and Obstacles to Success,Science270(5235): 404-410, 1995.
Culver, K., et al., Lymphocytes as cellular vehicles for gene therapy in mouse and man,Proc. Nat. Acad. Sci. USA88: 3155-3159, 1991.
Del Cerro, M., et al., Transplantation of Y79 Cells Into Rat Eyes: an In Vivo Model of Human Retinoblastomas,Invest. Opthalmol. Vis. Sci. 34: 3336-3346, 1993.
Docherty, K., Gene therapy for diabetes mellitus,Clin. Sci. 92: 321-330, 1997.
Dong, H., et al, Challenges for Gene Therapy of Type 1 Diabetes,Current Gene Therapy2: 403-414, 2002.
Dufour, J. et al., Biology of Reproduction, 64:S1-272 (2001).
Dufour, J., et al., Genetically engineered Sertoli cells are able to survive allogeneic transplantation,Gene Therapy11: 694-700 (2004).
Dufour, J., et al., Transgenic Sertoli Cells as a Vehicle for Gene Therapy,Cell Transplantation13: 1-6 (2004).
Ebendal, T., et al., Engineering cells to secrete growth factors,J. Neurol. 241: S5-S7, 1994.
Ebert, K., et al., A Moloney MLV-Rat Somatotropin Fusion Gene Produces Biologically Active Somatotropin in a Transgenic Pig,Mol. Endocrinol. 2(3): 277-283, 1988.
Fallaux, F., et al., Gene therapy for the hemophilias,Current Opinion in Hematology3: 385-389, 1996.
Flotte, T., et al., Adeno-associated Virus Vector Gene Expression Occurs in Nondividing Cells in the Absence of Vector DNA Integration,Am J. Respir. Cell Mol. Biol. 121: 517-521, 1994.
Flotte, T., et al., Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector,Proc. Natl. Acad. Sci. USA90: 10613-10617, 1993.
Freese, A., et al., Prospects for Gene Therapy in Parkinson's Disease,Movement Disorders11: 469-488, 1996.
Guillou, F., et al, Sertoli Cell-specific Expression of the Human Transferrin Gene,The Journal of Biolog
Gores Paul
Halberstadt Craig
Kirkpatrick Shaun A.
Finnegan Henderson Farabow Garrett & Dunner LLP
Ketter James
Sertoli Technologies, Inc.
LandOfFree
Production of a biological factor and creation of an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production of a biological factor and creation of an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of a biological factor and creation of an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2777357